Dacarbazine
(Synonyms: 达卡巴嗪; Imidazole Carboxamide) 目录号 : GC14485
A DNA alkylating prodrug
Cas No.:4342-03-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Dacarbazine, an antineoplastic chemotherapy drug used in the treatment of various cancers, among them malignant melanoma, Hodgkin lymphoma, sarcoma, and islet cell carcinoma of the pancreas. Dacarbazine is also a member of the class of alkylating agents, which destroy cancer cells by adding an alkyl group (CnH2n+1) to its DNA.[1] The alkyl group is attached to the guanine base of DNA, at the number 7 nitrogen atom of the purine ring.Cancer cells are more sensitive to DNA damage than normal cells, because its proliferate faster and with less error-correcting than healthy cells, but alkylating antineoplastic agent are also toxic to normal cells (cytotoxic), leading to damage, in particular in cells that divide frequently, as those in the gastrointestinal tract, bone marrow, testicles and ovaries.[2]
Dacarbazine is commonly used as a single agent in the treatment of metastatic melanoma in middle of 2006, and as part of the ABVD chemotherapy regimen to treat Hodgkin lymphoma, and in the MAID regimen for sarcoma.Currently, Dacarbazine combined with Oblimersen for the treatment of malignant melanoma in clinical trials.[3]Dacarbazine is normally administered by injection (a shot) or intravenous infusion (IV) under the immediate supervision of a doctor or nurse.Now in phase III about Melanoma Recurrent 2015 March.
References:1. "Alkylating Agents". US National Library of Medicine. Retrieved 2 August 2014.
2. Wiedemann GJ. et al. "Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma". European Journal of Cancer 1996,32A (5): 888–92.
3. MedLine, U.S. National Institutes of Health, National Library of Medicine.
4. CClinicalTrials.gov Identifier:NCT02288897.
| Cas No. | 4342-03-4 | SDF | |
| 别名 | 达卡巴嗪; Imidazole Carboxamide | ||
| 化学名 | (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide | ||
| Canonical SMILES | CN(C)NN=C1C(=NC=N1)C(=O)N | ||
| 分子式 | C6H10N6O | 分子量 | 182.18 |
| 溶解度 | ≥ 2.3mg/mL in DMSO, ≥ 0.54 mg/mL in Water, <0.49 mg/mL in EtOH | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.4891 mL | 27.4454 mL | 54.8908 mL |
| 5 mM | 1.0978 mL | 5.4891 mL | 10.9782 mL |
| 10 mM | 0.5489 mL | 2.7445 mL | 5.4891 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet